The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease
Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) Jg. 142; H. 1; S. 40 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
07.07.2020
|
| ISSN: | 1524-4539, 1524-4539 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.BACKGROUNDRivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.The current prespecified analysis was performed to assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ.METHODSThe current prespecified analysis was performed to assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ.A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable with longer treatment duration. The main drivers of NCB outcomes were "efficacy" events, in particular stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33], P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients with polyvascular disease (≥2 vascular beds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed.RESULTSA lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable with longer treatment duration. The main drivers of NCB outcomes were "efficacy" events, in particular stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33], P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients with polyvascular disease (≥2 vascular beds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed.Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.CONCLUSIONSCompared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424. |
|---|---|
| AbstractList | Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.BACKGROUNDRivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated measure of overall patient outcome.The current prespecified analysis was performed to assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ.METHODSThe current prespecified analysis was performed to assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death, stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ.A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable with longer treatment duration. The main drivers of NCB outcomes were "efficacy" events, in particular stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33], P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients with polyvascular disease (≥2 vascular beds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed.RESULTSA lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable with longer treatment duration. The main drivers of NCB outcomes were "efficacy" events, in particular stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33], P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients with polyvascular disease (≥2 vascular beds affected with atherosclerosis), impaired renal function, heart failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was observed.Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.CONCLUSIONSCompared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events, particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424. |
| Author | Shestakovska, Olga Eikelboom, John W Steffel, Jan Fox, Keith A A Anand, Sonia S Yusuf, Salim |
| Author_xml | – sequence: 1 givenname: Jan surname: Steffel fullname: Steffel, Jan – sequence: 2 givenname: John W surname: Eikelboom fullname: Eikelboom, John W – sequence: 3 givenname: Sonia S surname: Anand fullname: Anand, Sonia S – sequence: 4 givenname: Olga surname: Shestakovska fullname: Shestakovska, Olga – sequence: 5 givenname: Salim surname: Yusuf fullname: Yusuf, Salim – sequence: 6 givenname: Keith A A surname: Fox fullname: Fox, Keith A A |
| BookMark | eNpNjd9OwjAchRuDiYC-Q73zZth_K6t3s6iQIBAYekm68VuoGS2um_oWvrIkGGNyku8kX3JOD3Wcd4DQNSUDSiW91ZOlXk_TbDKfpeN0QBkZECGJSM5Ql8ZMRCLmqvOvX6BeCG-EEMmHcRd9ZzvAev68SFcrnNXWVHd4Bg3WlXW2MBW-BwelbbAv8dR_RiMfAC_th6n9l8mNw4uqDTgNB1tbh03A2u8PpoYtfrXN7k8cszCNBdeEk9C72h8P8IsJRVuZGo9sABPgEp2Xpgpw9cs-Wj8-ZHocTedPE51Oo4IrnkQxSCZJrgwwIRKWlzLOVZ6UpTQmEcBoEZfAhqVSyTahPJdyqKhSnFAB2zyhrI9uTruH2r-3EJrN3oYCqso48G3YMEFizjnjiv0A3lpsJw |
| CitedBy_id | crossref_primary_10_1007_s10557_025_07772_4 crossref_primary_10_1016_j_suc_2023_04_019 crossref_primary_10_1080_17425247_2025_2476043 crossref_primary_10_1016_j_diabres_2025_112244 crossref_primary_10_2147_IJGM_S289295 crossref_primary_10_1016_j_jvs_2025_02_002 crossref_primary_10_1016_j_cpcardiol_2022_101357 crossref_primary_10_4103_bc_bc_61_21 crossref_primary_10_1080_13543784_2021_1985463 crossref_primary_10_1097_CRD_0000000000000956 crossref_primary_10_2217_fca_2023_0051 crossref_primary_10_1016_j_heliyon_2024_e34602 crossref_primary_10_1016_j_hrthm_2024_05_045 crossref_primary_10_23736_S0392_9590_22_04861_1 crossref_primary_10_1038_s41569_023_00854_6 crossref_primary_10_1093_eurheartjsupp_suad034 crossref_primary_10_1016_j_jacc_2023_04_003 crossref_primary_10_1016_j_jacc_2021_04_083 crossref_primary_10_1177_17085381231193506 crossref_primary_10_1161_CIR_0000000000001005 crossref_primary_10_1093_ehjcvp_pvac028 crossref_primary_10_1080_14796678_2025_2522587 crossref_primary_10_1093_cvr_cvaa263 crossref_primary_10_1093_eurjpc_zwae038 crossref_primary_10_3390_ijms222212537 crossref_primary_10_1016_j_biopha_2021_111783 crossref_primary_10_1161_STROKEAHA_121_035208 crossref_primary_10_1055_a_2360_7551 crossref_primary_10_1016_j_atherosclerosis_2021_11_019 crossref_primary_10_3390_jcm13071956 crossref_primary_10_3389_fneur_2021_626106 crossref_primary_10_1161_JAHA_122_026553 crossref_primary_10_1177_19418744231161390 crossref_primary_10_1177_15266028241258659 crossref_primary_10_1016_j_jvs_2025_03_394 crossref_primary_10_3390_jcm10215083 crossref_primary_10_18087_cardio_2023_11_n2555 crossref_primary_10_23736_S0392_9590_25_05442_2 crossref_primary_10_1016_j_atherosclerosis_2024_118589 crossref_primary_10_1177_1358863X221122552 crossref_primary_10_3390_ijms22020954 crossref_primary_10_1055_a_1606_7523 crossref_primary_10_3390_jcm13144148 crossref_primary_10_3389_frai_2025_1540503 crossref_primary_10_1016_j_ahj_2024_03_002 crossref_primary_10_1080_14779072_2025_2488859 crossref_primary_10_1016_j_ejim_2024_10_012 crossref_primary_10_1016_j_jvs_2023_04_026 crossref_primary_10_15829_1560_4071_2025_6286 crossref_primary_10_1161_CIRCULATIONAHA_120_049768 crossref_primary_10_3390_medicina57070672 crossref_primary_10_1016_j_ejvs_2025_04_007 crossref_primary_10_1001_jamanetworkopen_2022_43201 crossref_primary_10_1016_j_jvs_2024_05_005 crossref_primary_10_1024_0301_1526_a001193 crossref_primary_10_15829_1728_8800_2021_2888 crossref_primary_10_2478_rjc_2025_0007 crossref_primary_10_1053_j_semvascsurg_2022_04_005 crossref_primary_10_1007_s00772_021_00840_7 crossref_primary_10_1097_CRD_0000000000000903 crossref_primary_10_3390_jcm14145157 crossref_primary_10_1016_j_ahj_2023_01_008 crossref_primary_10_23736_S0392_9590_21_04597_1 crossref_primary_10_1053_j_semvascsurg_2023_10_005 crossref_primary_10_1080_21688370_2021_1956284 crossref_primary_10_1161_STROKEAHA_123_043579 crossref_primary_10_3390_medicina60111781 crossref_primary_10_1002_rth2_12834 crossref_primary_10_1016_j_jacadv_2024_101440 crossref_primary_10_1093_eurjpc_zwab113 crossref_primary_10_1161_CIR_0000000000001168 crossref_primary_10_3390_ijms232314914 crossref_primary_10_1016_j_jacc_2020_12_053 crossref_primary_10_1097_XCS_0000000000000313 crossref_primary_10_3390_jcm14134401 crossref_primary_10_1024_0301_1526_a001174 crossref_primary_10_1097_MD_0000000000036915 crossref_primary_10_3390_jcm12247738 crossref_primary_10_1016_j_ejvs_2022_10_045 crossref_primary_10_1093_ehjcvp_pvad069 crossref_primary_10_1161_CIRCULATIONAHA_120_050723 crossref_primary_10_3390_ijms241311132 crossref_primary_10_23736_S0021_9509_23_12798_4 crossref_primary_10_1055_a_1857_5295 crossref_primary_10_1016_j_jvsvi_2024_100147 crossref_primary_10_3390_cells14171319 crossref_primary_10_1016_j_jacc_2024_03_383 crossref_primary_10_1016_j_jvs_2024_05_039 crossref_primary_10_1016_j_xkme_2022_100547 crossref_primary_10_1093_eurheartj_ehae179 crossref_primary_10_1016_j_lpm_2023_104164 crossref_primary_10_1055_a_2443_5122 crossref_primary_10_1016_j_pop_2023_07_005 crossref_primary_10_1093_eurheartj_ehae176 crossref_primary_10_1161_CIRCULATIONAHA_120_051368 crossref_primary_10_1186_s43044_025_00624_4 crossref_primary_10_1053_j_semvascsurg_2025_01_001 crossref_primary_10_1093_ehjcr_ytac201 crossref_primary_10_3389_fcvm_2022_1004473 crossref_primary_10_1093_eurjpc_zwaf218 crossref_primary_10_1093_ehjqcco_qcac026 crossref_primary_10_2174_0113816128259508231118141831 crossref_primary_10_1016_j_cjca_2024_07_002 |
| ContentType | Journal Article |
| DBID | 7X8 |
| DOI | 10.1161/CIRCULATIONAHA.120.046048 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ 7X8 AAAAV AAAXR AAFWJ AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY ADKSD ADSXY AE3 AE6 AEBDS AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DIWNM DU5 E3Z EBS EEVPB ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 |
| ID | FETCH-LOGICAL-c3938-5e6260b9ae24482bf65b9b8ff6aa84e21c5fe27f998d813b66791993014edb812 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 119 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00003017-202007070-00009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1524-4539 |
| IngestDate | Mon Sep 08 06:46:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3938-5e6260b9ae24482bf65b9b8ff6aa84e21c5fe27f998d813b66791993014edb812 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PQID | 2405333239 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2405333239 |
| PublicationCentury | 2000 |
| PublicationDate | 20200707 |
| PublicationDateYYYYMMDD | 2020-07-07 |
| PublicationDate_xml | – month: 07 year: 2020 text: 20200707 day: 07 |
| PublicationDecade | 2020 |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationYear | 2020 |
| SSID | ssj0006375 |
| Score | 2.6328342 |
| Snippet | Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared with ASA monotherapy in... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 40 |
| Title | The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease |
| URI | https://www.proquest.com/docview/2405333239 |
| Volume | 142 |
| WOSCitedRecordID | wos00003017-202007070-00009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELYKVKgXWl5q6UODhLi5kNixYy7VNhSBtCwrXt0bshNbjUSTQhZofwV_mbFjyqGXSkg5xZYSyeNvHt_oG0I2jEukRs9OK5MxykWpqFaVoxJdUVqWGIEEJabzoRyN8slEjWPBrYttlY-YGIC6aktfI99Cz4ORCUuZ-vLrivqpUZ5djSM0Zsgcw1DGW7WcPKmFCxaEdtFFccozpubJegAJkWwVB8fF2bAXnN33FcHtz54i5Pk_mBwczd7r5_7iG7IQQ0wY9DaxSF7YZoksDxpMr3_-gU0ITZ-hmr5E5g8jt75M7tFioDg6HA9OTuDU2-UOjOwUonLoJXxFWHT1FFoHw_aO7radheP6Vl-3v7XRDYwvbzoYeOa-bkB3UMT2dvheT3_8XcBn3Gu5dv1ClOeF89gTC7s9Z7RCzva-nRb7NI5roCVTCJuZ9cmRUdpiyJCnxonMKJM7J7TOuU0T39iWSocJXpUnzAghlW8fxCTNVgYDjVUy27SNfUuACSOlEVmSG82FyFQleYUf4dtc48v0HVl_PIELvA6e49CNbW-6i6czWPuPPe_Jq9Tnz6Fc-4HMObzy9iN5Wd5O6-76U7CmB3Em0Y4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+COMPASS+Trial%3A+Net+Clinical+Benefit+of+Low-Dose+Rivaroxaban+Plus+Aspirin+as+Compared+With+Aspirin+in+Patients+With+Chronic+Vascular+Disease&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Steffel%2C+Jan&rft.au=Eikelboom%2C+John+W&rft.au=Anand%2C+Sonia+S&rft.au=Shestakovska%2C+Olga&rft.date=2020-07-07&rft.issn=1524-4539&rft.eissn=1524-4539&rft.volume=142&rft.issue=1&rft.spage=40&rft_id=info:doi/10.1161%2FCIRCULATIONAHA.120.046048&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1524-4539&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1524-4539&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1524-4539&client=summon |